Article Text

Download PDFPDF

631 Development of highly efficacious and safe targeted cancer immunotherapy via IL12-based TMEkine™ platform

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.